| Comment | 1.100 | Kenneth P. Norquay, CMT | This is a penny stock and they tend to be promoted. | 2007-04-17 | |
| BUY | 7.430 | Ed Ho | A well-run company. Probably one of the lower risk biotech investments in Canada. Their product Onco TCS should be approved this year. Have a good marketing partnership with Enzon. | 2004-03-24 | |
| BUY | 4.550 | Andrew McCreath | If you like biotechs, this could be OK. Speculative. | 2003-05-29 | |
| DON'T BUY | 3.690 | David Baskin | Need to get FDA approval. Too speculative for their funds. | 2003-04-04 | |
| HOLD | 3.770 | Mike Weir | Good cash balance. Their problemsare delays in getting their product to market. Needs a good partner. | 2003-02-10 | |
| BUY | 4.140 | Mike Weir | Needs approval by FDA. Nice cash balance. | 2003-01-16 | |
| DON'T BUY | 4.900 | Glenn Paradis, BA, CFA | There will be some delay in their filings with FDA. | 2002-12-06 | |
| WEAK BUY | 6.500 | Bruce Cooper | In phase 3 trials. Speculative. | 2002-03-21 | |
| PAST TOP PICK | 7.150 | Martin Hubbes, CFA | (Was a top pick on Dec 5 no change) Still likes. | 2002-03-06 | |
| TOP PICK | 7.550 | Martin Hubbes, CFA | A speculative choice, but has a good RISK/RETURN. | 2001-12-05 | |
| BUY | 6.700 | Malvin Spooner | Just partnered which is good. Good company | 2001-05-04 | |
Experts that have talked about Inex Pharmaceuticals Corp
Rss Top Picks Feed
